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BACKGROUND:    Recurrence  of  hepatitis  C  after  liver
transplantation  is  an  almost  universal  occurrence.
T-cell derived cytokines have an important role in the
development of liver damage associated with chronic
hepatitis  C,  their  post-transplant  levels,  however,
have not been correlated with histologic recurrence
of the disease.
Aims: We sought to analyze levels of TNF-a , soluble IL-
2 receptor, IL-4 and IL-10 at 1 month, 6 months and 1
year after transplantation in 27 patients undergoing
transplantation for hepatitis C related end-stage liver
disease.
Methods:  HCV  RNA  levels  were  monitored  by  a
branched-chain DNA signal amplification assay. Diag-
nosis  of  recurrent  hepatitis  was  based  on  1-year
protocol biopsies and on biopsies performed for liver
enzyme elevations.
Results:  Recurrent  hepatitis  C  was  detected  in  52%
(n=14) of the 27 patients. HCV RNA levels rose over
time  in  all  patients  regardless  of  histologic  recur-
rence. TNF-a , and IL-4 levels, although elevated, did
not show specific patterns over time or in correlation
with  recurrence.  Similarly,  the  early  elevation  fol-
lowed by a gradual decrease over the first year in the
amount  of  soluble  IL-2  receptor  was  not  related  to
histologic  recurrence.  We  observed  a  significant
increase in circulating IL-10 levels over the first year
in  patients  with  biopsy-proven  recurrence,  while
patients  with  no signs of histologic  recurrence  dis-
played increased, but steady levels.
Conclusions:  These results  suggest  that  while  these
cytokines are associated with post-transplant recur-
rence of hepatitis C, their production may be altered
by additional factors.
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Introduction
Hepatitis  C  is  a  progressive  disease  that  leads  to
cirrhosis  in  approximately  20%  of  affected  individ-
uals1–3 and  has  emerged  as  the  most  common
indication for liver transplantation in both Europe and
the USA.4 Serologic recurrence of hepatitis C infec-
tion  after  transplantation  is  virtually  universal.5,6
Histologic recurrence has been observed in 30–70%
of patients within one year following transplantation
for  hepatitis C  related  end-stage  liver  disease.6–8 A
subset of these patients will develop allograft failure
as  a  result  of  hepatitis  C  recurrence  requiring  re-
transplantation.9
The  nature  of  the  injury  induced  by  chronic
hepatitis  C  infection  has  been  extensively  investi-
gated. Cytokines appear to play an important role in
the liver damage associated with chronic hepatitis C
via a variety of mechanisms, including activation of T
lymphocytes,10 direct hepatocellular  damage,11 and
by  modulation  of  both  the  viral-specific  immune
response12,13 and  viral  replication.14,15 The  relation
between  changes  in  cytokine  patterns  and  post-
transplant  recurrence  of  hepatitis  C,  however,  is
unclear.
This  study  was  designed  to  evaluate  cytokine
profiles (TNF-a , IL-4, IL-10, and the soluble receptor
of IL-2 [sIL-2R]) over the first year following primary
orthotopic liver transplantation (OLTx) for liver fail-
ure secondary to hepatitis C and to correlate these




Twenty-seven  patients  transplanted  for  liver  failure
secondary to hepatitis C cirrhosis between February
1994 and December 1996 were included in this study.
ISSN 0962-9351 print/ISSN 1466-1861 online/01/010037-05 © 2001 Taylor & Francis Ltd 37
DOI: 10.1080/09629350020012003562 7
Short Communication
Mediators of Inflammation, 10, 37–41 (2001)Patients  undergoing  transplantation  for  hepatitis  C
with  hepatocellular  carcinomas  requiring  adjuvant
chemotherapy (i.e.,  tumors  >3cm or with  vascular
invasion),  or  with  positive  serology  for  hepatitis B
surface antigen were excluded. Informed consent was
obtained from all patients prior to enrollment.
OLTx
All patients received induction immunotherapy with
OKT3 followed by triple immunosuppression therapy
with cyclosporine, azathioprine and steroids. Patients
were converted to tacrolimus for recurrent or severe
rejection  episodes  or  for  side  effects  of
cyclosporine.
Sample collection
Serum samples were obtained from each patient pre-
operatively and at 1 month, 6 months and 1 year after
transplantation. All samples were aliquoted into cryo-
tubes and stored at –80°C until analyzed.
Hepatitis C virus RNA levels
RNA  levels  were  determined  in  duplicate  by  a
branched-chain  DNA  signal  amplification  assay
(Chiron  HCV  RNA  1.0,  Chiron Diagnostics, Emery-
ville, CA). Actual hepatitis C viral concentrations were
computed  for  each  sample  using  a  standard curve
provided by the manufacturer.
Cytokine levels
Serum cytokines were measured using commercially
available ELISA kits for IL-10, IL-4, sIL-2R and TNF-a
(Immunotech, France) following  the manufacturer’s
instructions. Actual  cytokine levels  were  calculated
for  each  cytokine  using  a  specific  standard  curve
supplied  by  the  manufacturer.  According  to  the
manufacturer, there are no detectable levels of these
cytokines in normal human sera.
Diagnosis of recurrence
The diagnosis of recurrent hepatitis was made histo-
logically by examination of 1-year protocol biopsies
and/or examination of  biopsies  performed for liver
enzyme elevations. Histologic diagnosis was based on
the  presence  of:  (1)  diffuse  necroinflammatory
lesions  within  the  parenchyma  in  the  absence  of
acute  cellular  rejection  and  other  causes  of  acute
hepatitis  (e.g.,  CMV,  hepatitis  B,  drugs)  along with
dense lymphoid aggregates and lymphoid follicles in
the  portal  tracts,  or  (2)  piecemeal  necrosis  and
bridging necrosis in the absence of other causes.
Statistical analysis
All data were expressed as the mean±SD. Data were
analyzed with ANOVA. Only p values <0.05 following




Biopsy-proven histologic evidence of hepatitis recur-
rence was evident in 52% (n=14) of the 27 patients.
Hepatitis C viral RNA levels
Serum levels of hepatitis C viral RNA are shown in Fig.
1. All  patients  had evidence of  hepatitis  C  viremia
after transplantation, regardless of evidence of histo-
logic  recurrence  of  hepatitis.  Over  the  first  year
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FIG. 1. HCV RNA levels in patients transplanted for hepatitis C related liver failure.following  transplantation, viral  RNA  levels  rose  sig-
nificantly in patients with and without recurrence. No
significant  differences in  viral levels  were observed
between the two patient groups at any time point.
TNF-a levels
Serum  levels  of TNF-a were  considerably  elevated
following transplantation and remained elevated over
the first year in both patient groups. No significant
differences were observed over time in either group
or between the 2 patient groups (Table 1).
sIL-2R levels
A moderate elevation in levels of sIL-2R was observed
in  both patient groups  at 1  month following  trans-
plantation. In  both groups,  there  was a  decreasing
trend  over  the  first  year  regardless  of  histologic
recurrence,  with  no  differences  between  the  2
patient groups (Table 1).
IL-4 levels
No significant differences in IL-4 levels were observed
over time in either group or between the 2 patient
groups (Table 1).
IL-10 levels
Changes in serum levels of IL-10 are shown in Fig. 2.
In patients without histologic evidence of recurrence,
levels of IL-10 were elevated after transplantation but
did not vary significantly over the first year. On the
other hand, in patients with histologic evidence of
recurrence, IL-10  levels dramatically increased over
time,  with  a  statistically  significant  difference
between  1  month  and  1  year  (p<0.01),  as  well  as
between 6 months and 1 year (p<0.01). Additionally,
there  was  a  considerably  significant  difference
between IL-10 levels in the 2 patient groups at 1 year
(p<0.05).
Discussion
The  immunologic  mechanisms  involved  in  chronic
hepatitis  C-related  liver  injury  are  not  fully  under-
stood, and these events may be even more complex in
recurrent  hepatitis  C  following  transplantation.
Intense immunosuppression,16,17 pre-transplantation
viral  load,  post-transplantation  changes  in  viral
level,9,18 and  the  viral  genotype19 have  all  been
postulated to affect hepatitis C recurrence following
liver transplantation.
Recurrent hepatitis C and cytokines
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Table 1. Serum cytokine levels in patients transplanted for hepatitis C related liver failure







TNF-a (pg/ml) 300 ± 144 324 ± 1136 312 ± 1115 351 ± 1151 315 ± 1122 341 ± 1139
sIL-2R (pg/ml) 102 ± 197 91 ± 1123 68 ± 151 65 ± 166 58 ± 155 57 ± 161
IL-4 (pg/ml) 199 ± 1195 331 ± 1329 267 ± 1165 286 ± 1233 250 ± 1290 315 ± 1317
FIG. 2. IL-10 levels in patients transplanted for hepatitis C related liver failure.In the present study, we observed that in patients
who  undergo  liver  transplantation  for  hepatitis  C
infection, viral levels rise over the first year regard-
less of histologic recurrence. Furthermore, the quan-
tity  of  circulating  virus  did  not  correlate  with  the
finding of histologic recurrence. These observations
support those of previous studies, which have found
that viremia develops in almost all patients after liver
transplantation for hepatitis C and that the severity
of recurrent hepatitis C does not correlate with viral
levels.11,20,21
Cytokines are crucial mediators of  tissue homeo-
stasis.  As  important  co-stimulators  of  T-cell  activa-
tion,  cytokines  function  to  broaden  the  allograft
immune  response  by  recruiting  other  cells  and
stimulating  the  expression  of  adhesion  molecules.
In  chronic  liver  diseases,  cytokine  profiles  are
known to vary according to the specific etiology as
well  as  disease  severity.22–24 The  T-helper  type  1
(Th-1)/T-helper  type  2  (Th-2)  paradigm  is  based
upon  distinct  cytokine  secretion  patterns  from  2
sub-populations  of  CD4+ T-helper lymphocytes.25,26
Th-1 cells are involved in cellular immunity, and Th-
1  related  cytokines  (IL-2, TNF-a ,  IFN-g )  are  impor-
tant  in  the  host  antiviral  immune  response.
Th-2  cells  are  central  to  humoral  immunity,  while
Th-2 related cytokines (IL-4, IL-10) have major neg-
ative  immunoregulatory  functions.  A  shift  in
Th-1/Th-2  balance  might  be  involved  in  disease
progression.10,22,26,27
The cytokines chosen for evaluation in this study
all play important roles in humoral and cell-mediated
immunity,  as  they  represent  both  the Th-1  (sIL-2R,
TNF-a ) and Th-2 (IL-4, IL-10) arms of T-cell response.
Since all these cytokines are known to be  elevated
in  chronic  hepatitis  C,  monitoring  their  levels  fol-
lowing  transplantation  offers  a  unique  opportunity
to investigate  their possible  association with  recur-
rent hepatitis C. The increased levels of these media-
tors  following  OLTx  in  patients  with  liver  failure
secondary  to  hepatitis  C  represent  an  activated T
lymphocyte response.
In  patients  with  chronic  hepatitis  C, TNF-a has
been observed to regulate hepatocyte damage and to
be  present  in  increased  levels.2,23,28–31 While  we
observed significantly  elevated levels of TNF-a over
the  first  year  following  liver  transplantation  in
patients with and without recurrence, there was no
correlation  between  TNF-a levels  and  histologic
recurrence or viral RNA levels.
Increased  release  of  sIL-2R,  a  marker  of  T  cell
activation, has also been reported by several groups
in patients with chronic hepatitis.2,15,32–35 The mod-
erate  increase  in  sIL-2R  levels  described  in  the
present  study  1  month  following  liver  transplanta-
tion was irrespective of outcome and may reflect the
effects  of  the  intense  immunosuppression  on  acti-
vated T cells. Indeed, earlier we reported that sIL-2R
levels increased during the first week after OLTx in
patients  with  hepatitis  C,  with  the  highest  levels
measured  in  patients  whose  primary  immune  sup-
pression  was  OKT3,  likely  denoting  the  marked
degree  of  cytolysis  which  occurs  following  OKT3
administration.36
IL-4 is involved in the humoral immune response.
Its effects have been observed to be associated with
the  progression  of  viral  infections,  and  its  produc-
tion  is  known  to  be  enhanced  in  patients  with
chronic  hepatitis  C.10,12,22 Increased  expression  of
IL-4 has been linked to the development of hepatitis
C  chronicity.37 In  this  study,  we  observed  signifi-
cantly  elevated  levels  of  IL-4  that  were  sustained
over the first year following transplantation, but we
saw no specific patterns that correlated with histo-
logic recurrence or viral load.
IL-10 is known to inhibit many effector functions
of  the  immune  system.12,13,38 Its  production  has
also been observed to be  significantly  enhanced in
patients  with  chronic  active  hepatitis  C.10,39
We  found  increased levels  of  IL-10  in  both patient
groups  following  transplantation.  An  immediate/
early  post-transplantation increase in systemic IL-10
levels, which quickly returned to normal values, has
been  reported  and  was  associated  with  possible
activation of the graft’s macrophages.40 The changes
in  the  post-transplant  pattern  of  systemic
IL-10  levels  reported  here  for  the  first  time  –  a
dramatic  increase over  the  first  year  only  in  those
patients  with  histologic  evidence  of  recurrence  –
support  that  IL-10  may  be  related  to  the  develop-
ment  of  hepatitis  C  chronicity.37 Increased  levels
of  IL-10  inhibit  the  development  of Th-1  effector
mechanisms, leading to decreased IFN-g production
and  antiviral  response.33 While  persistent  HCV
replication  was  shown  to  be  associated  with
the  release  of  IL-10  in  other  studies,39 the
fact  that  in  our  patients  HCV-RNA  levels  rose
over  the  first  year  regardless  of  histological  evi-
dence  of  recurrence  suggest  a  more  complex,  yet
unclear  role  for  IL-10  in  post-transplant  recurrent
hepatitis C.
Our  findings  indicate  that  after  liver  transplanta-
tion for hepatitis C, production of these 4 cytokines
is not exclusively  driven by  disease recurrence but
may  be  altered  by  confounding  factors,  including
graft  damage,  allo-specific  immune  response  and
immunosuppression.  While  induction  immunother-
apy  was  uniformly  achieved  with  OKT3  among
these patients, the sampling schedule did not allow
us to correlate cytokine levels to important clinical
variables  such  as  ischemia/reperfusion  damage,
frequency  and  treatment  of  rejection  episodes,  or
infection.  Since  these  mediators  may  serve  as
possible  targets  for  treatment  of  post-transplant
recurrent  hepatitis  C,  further  investigations  are
warranted.
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